Below you will find a slew of scientific articles, some of which are drier than my mother’s Thanksgiving turkey! They are, however, extremely valuable when it comes to understanding schizophrenia spectrum disorders ( and bipolar disorder, too), the disease’s progression, its treatment, the results from longitudinal studies and what those results mean, as well as what medications are proving to be most effective. Why should you or I, lay people, be reading them? Because we are the advocates, and the healthcare industry is changing. We can no longer afford to be wide-eyed innocents completely ignorant of what’s going on in the behavioral health communities at large. At the least, we have to come armed with valid questions that will lead to substantive answers which will then provide appropriate directions for next steps. In the 21st. century, it all begins with YOU and ME…and the right information. So, here’s some really cool stuff that might get you started or keep you going.**
“Visualizing Schizophrenia”, Irene Wielawski, New York Times, June 13, 2008.
“Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia”, Andreasen et al, Biological Psychiatry, October 1, 2011.
“Depakote, Lithium Shown Effective in Treating Childhood Bipolar Disorder“, PsychCentral, Reviewed by John M. Grohol, Psy.D. on October 26, 2007.
“Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial”, Rasmus W Licht, The Lancet, Volume 375, Issue 9712, 30 January–5 February 2010, Pages 385–395.
“The Role of Vitamins and Minerals in Psychiatry“, Stacey Cornish and Lewis Mehl-Madrona, Integrative Medicine Insights 2008:3 33-42.
“Cognition and communication dysfunctions in early-onset schizophrenia: Effect of risperidone”, Remberk at al, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 39, Issue 2, 3 December 2012, Pages 348–354.
“Antipsychotic Medicines for Children and Teens: A Review of The Research for Parents and Caregivers“, U.S. Department of Health and Human Services
“One-year double-blind study of the neurocognitive efficacy of olanzipine, risperidone, and haloperidol in schizophrenia“, Keefe et al, Schizophrenia Research, Volume 81, Issue 1, 1 January 2006, Pages 1–15.
“New Possibilities in Cognition Enhancement for Schizophrenia“, Green, Michael F. American Journal of Psychiatry, Vol, 166, No. 7, July 1, 2009.
“Brain chemical finding could open door to new schizophrenia drugs”, Phys.org, September 30, 2010. Source: J.M. Stone et al. “Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis.” Biological Psychiatry, 1 October 2010.
“Dopamine synthesis capacity in patients with treatment-resistant schizophrenia“, Demhaha, A. et al, American Journal of Psychiatry, November 2012.
“Altered Brain Activity Responsible for Cognitive Symptoms in Schizophrenia” MedicalExpress.com, March 20, 2013. Source: Neuron, Parnaudeau et al. “Inhibition of medio-dorsal thalamus disrupts thalamo-frontal connectivity and cognition.”
“Diagnostic Challenges of Schizophrenia versus Schizoaffective Disorder (transcript with slides)” Gustavo Alva, MD Medical Director, ATP Clinical Research, Costa Mesa, Callifornia.
The Role of Mitochondria Dysfunction in Psychiatric Disease. Scaglia, Fernando, Department of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas
The Neurodevelopmental Hypothesis of Schizophrenia, Revisited. S. Hossein Fatemi and Timothy D. Folsom, Schizophrenia Bulletin (2009) 35 (3):528-548. First published online: February 17, 2009
Age-dependent changes in prefrontal intrinsic connectivity, Proceedings of the National Academy of Sciences, Published online before print on February 24, doi:10.1073/pnas.1316594111 (Medicalxpress associated article)
Neurocognitive Decline in Early-Onset Schizophrenia Compared with ADHD and Normal Controls: Evidence from a 13-Year Follow-Up Study. Merete Øie, Kjetil Sundet, and Bjørn Rishovd Rund, Oxford Journals, Schizophrenia Bulletin, Volume 36, Issue 3, p. 557-565. Oxford University Press, 2008.
Schizophrenia not a single disease but multiple genetically distinct disorders. Arnedo J, Svrakic DM, del Val C, Romero-Zaliz R, Hernandez-Cuervo H, Fanous AH, Pato MT, Pato CN, de Erausquin GA, Cloninger CR, Zwir I. Uncovering the hidden risk architecture of the schizophrenias: Confirmation in three independent genome-wide association studies. The American Journal of Psychiatry. vol. 172 (2), 2014. Published online Sept. 15, 2014.
Schizophrenia onset linked to elevated neuron levels. Originally appeared in Neuroscience.
Schizophrenia risk from complex variation of complement component 4. appeared in Nature and summarized in Gizmodo
**This will be expanded as I read more articles.